.jpg "Wedbush Thinks United Therapeutics")
Wedbush analyst Liana Moussatos reiterated a Buy rating on United Therapeutics (NASDAQ: UTHR) today and set a price target of $234. The company’s shares opened today at $102.02, close to its 52-week low of $100.76.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 8.5% and a 41.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on United Therapeutics is Hold and the average price target is $135.83, representing a 33.1% upside.
In a report issued on May 2, Oppenheimer also assigned a Buy rating to the stock with a $180 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $152.55 and a one-year low of $100.76. Currently, United Therapeutics has an average volume of 439.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
